A 48-year-old man with known chronic hepatitis B (HBeAg positive, HBV DNA 8 × 10^6 copies/mL) and compensated cirrhosis presents for treatment initiation. He has no prior antiviral exposure. What is the preferred first-line regimen?

Explanation

## Chronic Hepatitis B: First-Line Antiviral Therapy **Key Point:** Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) are the preferred first-line nucleotide reverse transcriptase inhibitors (NRTIs) for treatment-naïve chronic HBV, especially in advanced disease (cirrhosis). ### Why TDF is Preferred in This Case 1. **High barrier to resistance:** TDF has a high genetic barrier to resistance; resistance is rare even with prolonged use 2. **Potent HBV suppression:** Achieves rapid and profound reduction in HBV DNA 3. **Cirrhosis indication:** In patients with cirrhosis, high-potency antivirals are essential to prevent decompensation 4. **Monotherapy efficacy:** TDF monotherapy is sufficient; combination therapy is not required for first-line treatment 5. **Renal safety:** TDF requires baseline and periodic renal function monitoring, but is safe in most patients **High-Yield:** TAF (tenofovir alafenamide) is a newer formulation with better renal and bone safety than TDF, but both are acceptable first-line agents. TDF is more widely available in resource-limited settings. ### Treatment Indications in This Patient - HBeAg positive with HBV DNA >10^5 copies/mL ✓ - Compensated cirrhosis ✓ - ALT elevation (presumed) ✓ **Clinical Pearl:** Patients with cirrhosis require treatment regardless of ALT level because of the risk of decompensation. HBV DNA >10^5 copies/mL in HBeAg-positive disease is a strong indication for treatment. ### Comparison of First-Line Options | Agent | Barrier to Resistance | Potency | Cirrhosis Use | Monotherapy Adequate? | |-------|----------------------|---------|---------------|-----------------------| | **TDF/TAF** | High | Very high | Preferred | Yes | | Entecavir | Moderate-high | Very high | Acceptable | Yes (but less ideal than TDF) | | Lamivudine | Low | Moderate | Not recommended | No — high resistance rate | | IFN-α | N/A | Moderate | Contraindicated in cirrhosis | No — risk of decompensation | **Warning:** Lamivudine monotherapy should NOT be used as first-line because of a high rate of resistance-associated mutations (70% at 5 years). It is now reserved for pregnant women (safer profile) or as add-on therapy in specific scenarios. **Warning:** Interferon-alpha is contraindicated in decompensated cirrhosis and is poorly tolerated in compensated cirrhosis due to risk of hepatic decompensation. It is rarely used in modern HBV management. ### Why Entecavir Is Not Preferred Over TDF While entecavir is a potent nucleoside analogue with a high barrier to resistance, TDF is preferred because: - TDF is a nucleotide (broader spectrum activity) - TDF has superior HBV suppression in some studies - TDF has activity against HIV (if co-infection is discovered later) - Entecavir has rare cases of resistance in treatment-naïve patients with high viral loads [cite:Harrison 21e Ch 297; AASLD/IDSA HBV Guidance 2018]